Methanobrevibacter

Archaeal Biology—Not Bacteria#

Archaea are a distinct domain of life, separate from Bacteria and Eukarya. Methanobrevibacter has a fundamentally different cell wall (pseudopeptidoglycan rather than peptidoglycan), membrane lipids (ether-linked isoprenoids), and metabolic machinery.

Despite being non-bacterial, M. smithii is detected by 16S rRNA sequencing and is increasingly recognized as an important functional member of the Gut Microbiome.

Estimated to colonize 70-80% of human guts, reaching densities of 10^8 to 10^10 organisms per gram of stool.

Metal Dependencies#

Methanobrevibacter is among the most metal-dependent organisms in the human gut. Nickel: The key enzyme methyl-coenzyme M reductase (MCR) contains coenzyme F430, a nickel (Ni)-tetrapyrrole unique to methanogens. Without nickel, methanogenesis cannot occur.

This makes Methanobrevibacter exquisitely sensitive to nickel availability and competition.

Cobalt: Required for corrinoid cofactors involved in methyl group transfer during methanogenesis. Iron: iron (Fe)-S clusters are essential for Hydrogenase enzymes that oxidize H2—the first step of hydrogenotrophic methanogenesis. Zinc: Structural roles in metalloenzymes.

Copper sensitivity: copper (Cu) is toxic to methanogens at very low concentrations (1.9 umol/L inhibits the related Methanococcus maripaludis). Zinc at 1.0 mmol/L can rescue copper toxicity through competitive transporter interactions.^{[1]The physiological effect of heavy metals and volatile fatty acids on Methanococcus maripaludis S2Abdel Azim A, Rittmann SKR, Fino D et al. · 2018Open reference 1 ↓}

Role in Gut Ecosystem#

Consumes H2 produced by bacterial fermentation, maintaining low partial pressure of H2 that thermodynamically favors continued bacterial fermentation and SCFA production. Without methanogenic H2 disposal, H2 accumulation would inhibit NADH reoxidation in fermentative bacteria, slowing the entire gut fermentation process.

Competes with sulfate-reducing bacteria Desulfovibrio and reductive acetogens for available H2. Methane production slows colonic transit (CH4 inhibits smooth muscle contractility), linking Methanobrevibacter abundance to constipation.

Multiple Sclerosis#

Increased in MS patients in the landmark Jangi 2016 study, alongside Akkermansia muciniphila.^{[2]Alterations of the human gut microbiome in multiple sclerosisSushrut Jangi, Roopali Gandhi, Laura M. Cox et al. · 2016Open reference 2 ↓}

Positively correlated with pro-inflammatory gene expression: dendritic cell maturation, interferon signaling, NF-kB Signaling Pathway signaling, CASP1, TRAF5, and STAT5 in circulating T cells and monocytes.

MS patients show elevated breath methane consistent with increased gut Methanobrevibacter abundance. LPS-like molecules from Methanobrevibacter activate inflammatory cells and dendritic cells. Expresses adhesin-like proteins enabling mucosal adhesion, placing it near gut-associated lymphoid tissue where it can stimulate immune responses.

Constipation-Predominant IBS#

Elevated in IBS-C (constipation-predominant irritable bowel syndrome), consistent with methane's inhibitory effect on colonic motility. Breath methane testing is used clinically to identify methane-predominant IBS patients who may benefit from targeted antimicrobial therapy (rifaximin + neomycin).

Key Metabolites#

Methane (CH4)—inhibits colonic motility; contributes to breath methane as clinical biomarker. Short-chain lipids—cell membrane ether lipids unique to archaea.